Skip to content
Aperlena

Ireland - Laboratory reagents - Provision of Flow Cytometry Reagents, Antibodies, Platform-Specific Consumables and Single-Cell Genomics Reagents for Ongoing Research Activities

Awarded Contract award No deadline published
Watch this tender

Bidding is closed. An award or a correction on this notice: an email when the register sees it. Log in

  1. Awarded
  2. Published

Description

This voluntary ex-ante transparency (VEAT) notice acknowledges that Trinity College Dublin proposes to put in place a contract with Becton Dickinson UK Ltd, 1030 Eskdale Road, Winnersh Triangle, Wokingham, Berkshire RG41 5TS for the provision of flow cytometry reagents, antibodies, platform-specific consumables and single-cell genomics reagents required to support ongoing research activities across the University. The requirement encompasses specialised laboratory reagents, including fluorochrome-conjugated monoclonal antibodies, staining buffers, assay kits, instrument calibration materials, and proprietary consumables associated with BD flow cytometry and BD Rhapsody single-cell genomics platforms. These products are integral to established experimental workflows across multiple research groups, including immunophenotyping, cell signalling analysis and single-cell gene expression studies. Trinity College Dublin intends to award this contract in accordance with Article 32(2)(b)(ii) of Directive 2014/24/EU, on the basis that competition is absent for technical reasons. The required reagents are defined by specific antibody clones and fluorochrome conjugations, many of which are proprietary and are embedded within validated experimental protocols. Substitution would necessitate extensive re-validation, introduce scientific risk and delay research outputs. In addition, platform-specific consumables, including BD Rhapsody cartridge and cDNA kits are required for the operation of existing instrumentation and cannot be replaced with alternative products. While certain items may be available via resellers, this does not represent a viable alternative, as it introduces additional cost without addressing technical compatibility or continuity requirements. Accordingly, the proposed approach is necessary to ensure continuity of research and represents a proportionate and compliant procurement solution. This voluntary ex-ante transparency (VEAT) notice acknowledges that Trinity College Dublin proposes to put in place a contract with Becton Dickinson UK Ltd, 1030 Eskdale Road, Winnersh Triangle, Wokingham, Berkshire RG41 5TS for the provision of flow cytometry reagents, antibodies, platform-specific consumables and single-cell genomics reagents required to support ongoing research activities across the University. The requirement encompasses specialised laboratory reagents, including fluorochrome-conjugated monoclonal antibodies, staining buffers, assay kits, instrument calibration materials, and proprietary consumables associated with BD flow cytometry and BD Rhapsody single-cell genomics platforms. These products are integral to established experimental workflows across multiple research groups, including immunophenotyping, cell signalling analysis, and single-cell gene expression studies. Trinity College Dublin intends to award this contract in accordance with Article 32(2)(b)(ii) of Directive 2014/24/EU, on the basis that competition is absent for technical reasons. The required reagents are defined by specific antibody clones and fluorochrome conjugations, many of which are proprietary, and are embedded within validated experimental protocols. Substitution would necessitate extensive re-validation, introduce scientific risk, and delay research outputs. In addition, platform-specific consumables, including BD Rhapsody cartridge and cDNA kits, are required for the operation of existing instrumentation and cannot be replaced with alternative products. While certain items may be available via resellers, this does not represent a viable alternative, as it introduces additional cost without addressing technical compatibility or continuity requirements. Accordingly, the proposed approach is necessary to ensure continuity of research and represents a proportionate and compliant procurement solution.

Official source

Source: TED - Tenders Electronic Daily (Publications Office of the EU)

Always verify details on the official notice.

Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 1 month ago

More from this buyer

Full buyer profile

7 open tenders right now

Recent awards

Change history

Every time an official source republished this notice with different content. We watch every source we index, including regional copies of the same notice.

  1. Read before bidding
    • Award date: Awarded on April 20, 2026
    • Scope and criteria: The description was expanded. Re-read it before you bid.

Follow this tender and we email you the moment it changes. Create account

Similar tenders

Market context

Avg. open tender · Medical equipment & pharmaceuticals
€10,142,739
9,882 open across Europe right now
Buyer track record on Aperlena
119 notices tracked · 84 awarded
€210,780,816 in awarded contracts

Never miss a tender like this

2 new notices in Medical equipment & pharmaceuticals in Ireland in the last 7 days. Get an email when new ones appear. Free.

Set up my alert

Keyboard shortcuts

Read a list without reaching for the mouse. The shortcuts stay quiet while you type in a field.

j
Next result
k
Previous result
Enter
Open the result
n
Next page
p
Previous page
c
Compare this result
s
Shortlist this result
/
Jump to the search box
?
Show these shortcuts
Esc
Close